Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · doi:10.1101/2021.05.22.21257658 · Cited by 2,888

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939

Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

(2021) · doi:10.1101/2021.06.01.21258172 · Cited by 425

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01449-9 · Cited by 425

The generation of stem cell-like memory cells early after BNT162b2 vaccination is associated with durability of memory CD8+ T cell responses

Jung, S., Jung, J. H., Noh, J. Y., Kim, W., Yoon, S., Jung, J., Kim, E. S., Kim, H. B., Cheong, H. J., Kim, W. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111138 · Cited by 25

SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines

Sunagar, R., Singh, A., & Kumar, S. (2023) · Vaccines · doi:10.3390/vaccines11040849 · Cited by 31

Changing Features of COVID-19: Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants in Southern Italy

Loconsole, D., Centrone, F., Morcavallo, C., Campanella, S., Accogli, M., Sallustio, A., Peccarisi, D., Stufano, A., Lovreglio, P., & Chironna, M. (2021) · Vaccines · doi:10.3390/vaccines9111354 · Cited by 27

Attitudes and Determinants of Mandatory Vaccination against COVID-19 among the General Population of Cyprus: A Nationwide Cross-Sectional Study

Giannakou, K., Kyprianidou, M., & Heraclides, A. (2022) · Vaccines · doi:10.3390/vaccines10030438 · Cited by 25

Modeling the Impact of Vaccination on COVID-19 and Its Delta and Omicron Variants

Wang, J., Chan, Y.-C., Niu, R., Wong, E. W. M., & van Wyk, M. A. (2022) · Viruses · doi:10.3390/v14071482 · Cited by 28

Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh

Haq, M. A., Roy, A. K., Ahmed, R., Kuddusi, R. U., Sinha, M., Hossain, M. S., Vandenent, M., Islam, M. Z., Zaman, R. U., Kibria, M. G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61922-6 · Cited by 30

Optimising vaccine immunogenicity in ageing populations: key strategies

Jiang, G., Zou, Y., Zhao, D., & Yu, J. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00497-3 · Cited by 27

Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults

Zhang, Y., Yang, Y., Qiao, N., Wang, X., Ding, L., Zhu, X., Liang, Y., Han, Z., Liu, F., Zhang, X., et al. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0914-x · Cited by 22

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects

Zarębska‐Michaluk, D., Hu, C., Brzdęk, M., Flisiak, R., & Rzymski, P. (2022) · Vaccines · doi:10.3390/vaccines10081223 · Cited by 24

Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS‐CoV‐2 vaccination

Hollstein, M. M., Münsterkötter, L., Schön, M. P., Bergmann, A., Husar, T. M., Abratis, A., Eidizadeh, A., Schaffrinski, M., Zachmann, K., Schmitz, Ä., et al. (2022) · Allergy · doi:10.1111/all.15247 · Cited by 21

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland

Rzymski, P., Pazgan−Simon, M., Kamerys, J., Moniuszko-Malinowska, A. M., Sikorska, K., Wernik, J., Zarębska‐Michaluk, D., Supronowicz, Ł., Sobala‐Szczygieł, B., Skrzat‐Klapaczyńska, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10040557 · Cited by 23

COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections

Jakimovski, D., Zakalik, K., Awan, S., Kavak, K. S., Pennington, P., Hojnacki, D. W., Kolb, C., Lizarraga, A., Eckert, S. P., Sarrosa, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10050695 · Cited by 22

SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review

Ledda, C., Costantino, C., Motta, G., Cunsolo, R., Stracquadanio, P., Liberti, G., Maltezou, H. C., & Rapisarda, V. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7010009 · Cited by 22

An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines

Al-Sheboul, S. A., Brown, B., Shboul, Y., Fricke, I., Imarogbe, C., & Alzoubi, K. H. (2022) · Vaccines · doi:10.3390/vaccines11010051 · Cited by 23

Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period

Kim, J. Y., Lim, S. Y., Park, S., Kwon, J., Bae, S., Park, J. Y., Cha, H. H., Seo, M. H., Lee, H. J., Lee, N., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab579 · Cited by 21

ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: Updated guidance for the era of vaccines and viral variants

Gralnek, I. M., Hassan, C., Ebigbo, A., Fuchs, A., Beilenhoff, U., Antonelli, G., Bisschops, R., Arvanitakis, M., Bhandari, P., Bretthauer, M., et al. (2021) · Endoscopy · doi:10.1055/a-1700-4897 · Cited by 21

Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection

Curlin, M. E., Bates, T. A., Guzman, G., Schoen, D., McBride, S. K., Carpenter, S. D., & Tafesse, F. (2022) · Med · doi:10.1016/j.medj.2022.09.001 · Cited by 21

Alpha, Beta, Delta, Omicron, and SARS-CoV-2 Breakthrough Cases: Defining Immunological Mechanisms for Vaccine Waning and Vaccine-Variant Mismatch

Hewins, B., Rahman, M., Bermejo-Martín, J. F., Kelvin, A. A., Richardson, C. D., Rubino, S., Kumar, A., Ndishimye, P., Ostadgavahi, A. T., Mahmud-Al-Rafat, A., et al. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.849936 · Cited by 21

Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era

Reedman, C. N., Drews, S. J., Yi, Q., Pambrun, C., & O’Brien, S. F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00339-22 · Cited by 20

Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

Baker, D., MacDougall, A. M., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2021) · Clinical & Experimental Immunology · doi:10.1093/cei/uxab015 · Cited by 21

Assessing the potential impact of immunity waning on the dynamics of COVID-19 in South Africa: an endemic model of COVID-19

Rabiu, M., & Iyaniwura, S. A. (2022) · Nonlinear Dynamics · doi:10.1007/s11071-022-07225-9 · Cited by 20

Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers

Brunner, W. M., Freilich, D., Victory, J. M., Krupa, N. L., Scribani, M., Jenkins, P., Lasher, E. G., Fink, A., Shah, A., Cross, P., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.08.022 · Cited by 19

COVID‐19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS‐CoV‐2 Omicron wave in the first quarter of 2022

Rzymski, P., Kasianchuk, N., Sikora, D., & Poniedziałek, B. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28131 · Cited by 19

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination

Assawakosri, S., Kanokudom, S., Chansaenroj, J., Suntronwong, N., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Duangchinda, T., Chantima, W., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.07.038 · Cited by 16

COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021

Machado, A., Kislaya, I., Rodrigues, A. P., Sequeira, D. J., Lima, J., Cruz, C., Leite, P. P., Dias, C. M., & Nunes, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274008 · Cited by 18

Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Pan, H., Liu, J., Huang, B., Li, G., Chang, X., Liu, Y., Wang, W., Chu, K., Zhu, D., Wu, J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab627 · Cited by 19

Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2

Zelini, P., d’Angelo, P., Cereda, E., Klersy, C., Sabrina, P., Albertini, R., Grugnetti, G., Grugnetti, A. M., Marena, C., Cutti, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10081993 · Cited by 18

Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis

Wankhede, D., Grover, S., & Hofman, P. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.072 · Cited by 18

A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned

O’Connor, M. A., Hawman, D. W., Meade-White, K. D., Leventhal, S. S., Song, W., Randall, S., Archer, J. F., Lewis, T. B., Brown, B., Fredericks, M., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011298 · Cited by 18

Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study

Kim, J. S., Sun, Y., Balte, P., Cushman, M., Boyle, R., Tracy, R. P., Styer, L. M., Bell, T. D., Anderson, M. R., Allen, N. B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45468-9 · Cited by 21

Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients

Bonfá, E., da silva, C., Medeiros-Ribeiro, A., Kupa, L. D. V. K., Yuki, E. F. N., Pasoto, S. G., Saad, C., Fusco, S. R. G., Pereira, R., Shinjo, S. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33042-0 · Cited by 17

Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals

Ogrič, M., Žigon, P., Podovšovnik, E., Lakota, K., Sodin‐Šemrl, S., Rotar, Ž., & Čučnik, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876533 · Cited by 15

Durability analysis of the highly effective BNT162b2 vaccine against COVID-19

Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Niesen, M. J. M., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Gordon, J. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac082 · Cited by 16

SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study

Brlić, P. K., Pavletić, M., Lerga, M., Krstanović, F., Matešić, M. P., Miklić, K., Malić, S., Mikša, L., Pajcur, M., Peruč, D., et al. (2022) · Viruses · doi:10.3390/v14091966 · Cited by 17

High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses

Akanmu, S. A., Herrera, B. B., Chaplin, B., Ogunsola, S., Osibogun, A. O., Onawoga, F., John‐Olabode, S., Akase, I. E., Nwosu, A. O., Hamel, D. J., et al. (2023) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2023.100156 · Cited by 14

The Pandemic Experience in Southeast Asia: Interface Between SARS-CoV-2, Malaria, and Dengue

Yek, C., Nam, V. S., Leang, R., Parker, D. M., Heng, S., Kimsan, S., Sovannaroth, S., Mayxay, M., AbuBakar, S., Sasmono, R. T., et al. (2021) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2021.788590 · Cited by 16

The public’s attitude to and acceptance of periodic doses of the COVID-19 vaccine: A survey from Jordan

Abuhammad, S., Khabour, O. F., Alzoubi, K. H., Hamaideh, S. H., Alzoubi, B. A., Telfah, W. S., & El-zubi, F. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271625 · Cited by 17

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Christensen, I. E., Jyssum, I., Tveter, A. T., Sexton, J., Tran, T. T., Mjaaland, S., Kro, G. B., Kvien, T. K., Warren, D. J., Jahnsen, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02587-8 · Cited by 18

Occupation, Worker Vulnerability, and COVID-19 Vaccination Uptake: Analysis of the Virus Watch prospective cohort study

Beale, S., Burns, R., Braithwaite, I., Byrne, T., Fong, W. L. E., Fragaszy, E., Geismar, C., Hoskins, S., Kovar, J., Navaratnam, A. M. D., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.080 · Cited by 15

Cohort Profile: Virus Watch—understanding community incidence, symptom profiles and transmission of COVID-19 in relation to population movement and behaviour

Byrne, T., Kovar, J., Beale, S., Braithwaite, I., Fragaszy, E., Fong, W. L. E., Geismar, C., Hoskins, S., Navaratnam, A. M. D., Nguyen, V. G., et al. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad087 · Cited by 16

mRNA vaccines against COVID‐19: a showcase for the importance of microbial biotechnology

Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13974 · Cited by 16

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection

Vietri, M. T., D’Elia, G., Caliendo, G., Passariello, L., Albanese, L., Molinari, A. M., & Angelillo, I. F. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.045 · Cited by 15

Acceptance, attitudes, and barriers of vaccine booster dose among nursing students: A multicounty survey

Al‐Mugheed, K., Rawajfah, O. A., Bani‐Issa, W., & Rababa, M. (2022) · Journal of Nursing Management · doi:10.1111/jonm.13791 · Cited by 19

Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study

Visos‐Varela, I., Zapata‐Cachafeiro, M., Piñeiro‐Lamas, M., Carracedo‐Martínez, E., Sáez, M., Herdeiro, M. T., Figueiras, A., & Salgado‐Barreira, Á. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.03.011 · Cited by 16

SARS-CoV-2 S protein disrupts the formation of ISGF3 complex through conserved S2 subunit to antagonize type I interferon response

Ni, W., Li, W., Cai, Z., Guo, W., Zheng, Y., Zhao, Y., Wu, Z., Liang, S., Ye, J., Guo, X., et al. (2024) · Journal of Virology · doi:10.1128/jvi.01516-24 · Cited by 18

Hesitancy towards the Third Dose of COVID-19 Vaccine among the Younger Generation in Japan

Khan, M. S. R., Nguyen, T. X. T., Lal, S., Watanapongvanich, S., & Kadoya, Y. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127041 · Cited by 15

Transmission and Risk Factors of COVID-19 among Health Care Workers

Alghader, M., Valvi, D., & de la Hoz, R. E. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1766118 · Cited by 15

COVID boosters for wealthy nations spark outrage

Maxmen, A. (2021) · Nature · doi:10.1038/d41586-021-02109-1 · Cited by 15

Waning immunity and the future of booster vaccination strategies in global vaccine programs post COVID-19

Biswas, R., Roy, A., Kayal, T., Basu, S., Ghosh, S., Ramaiah, S., & Anbarasu, A. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2626088 · Cited by 15

Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection

Wang, F., Huang, B., Deng, Y., Zhang, S., Liu, X., Wang, L., Liu, Q., Zhao, L., Tang, L., Wang, W., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02942-3 · Cited by 14

Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine

Farahmand, B., Larijani, M. S., Fotouhi, F., Biglari, A., Sorouri, R., Amiri, F. B., Eslamifar, A., Jalali, T., Salehi-Vaziri, ‪., Banifazl, M., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20555 · Cited by 14

Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization

Jiang, W., Maldeney, A. R., Yuan, X., Richer, M. J., Renshaw, S. E., & Luo, W. (2024) · Cell Reports · doi:10.1016/j.celrep.2023.113665 · Cited by 16

Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring

Moeller, M. E., Engsig, F. N., Bade, M., Fock, J., Pah, P., Soerensen, A. L., Bang, D., Donolato, M., & Benfield, T. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00396-22 · Cited by 14

Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals

Jeewandara, C., Aberathna, I. S., Gomes, L., Pushpakumara, P. D., Danasekara, S., Guruge, D., Ranasinghe, T., Gunasekera, B., Kamaladasa, A., Kuruppu, H., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.592 · Cited by 14

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

Priddy, F. H., Williams, M., Carson, S., Lavender, B., Mathieson, J., Frampton, C., Moreland, N. J., McGregor, R., Williams, G., Brewerton, M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.07.009 · Cited by 16

Trajectory and Demographic Correlates of Antibodies to SARS-CoV-2 Nucleocapsid in Recently Infected Blood Donors, United States

Haynes, J. M., Dodd, R. Y., Crowder, L. A., Notari, E. P., & Stramer, S. L. (2023) · Emerging infectious diseases · doi:10.3201/eid2907.230173 · Cited by 14

Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection

Hueda-Zavaleta, M., de la Torre, J. C. G., Cáceres-DelAguila, J. A., Muro-Rojo, C., Cruz-Escurra, N. D. L., Siles, D. A., Minchón-Vizconde, D., Corzo, C. A. C., Bardales-Silva, F., Benites-Zapata, V. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10040502 · Cited by 14

Immunodominant SARS‐CoV‐2‐specific CD4+ and CD8+ T‐cell responses elicited by inactivated vaccines in healthy adults

Ning, J., Wang, Q., Chen, Y., He, T., Zhang, F., Chen, X., Shi, L., Zhai, A., Li, B., & Wu, C. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28743 · Cited by 12

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose

Ruggieri, S., Aiello, A., Tortorella, C., Navarra, A., Vanini, V., Meschi, S., Lapa, D., Haggiag, S., Prosperini, L., Cuzzi, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108525 · Cited by 13

Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection

Seow, J., Shalim, Z. A., Graham, C., Kimuda, S., Pillai, A., Lechmere, T., Kurshan, A., Khimji, A. M., Snell, L. B., Nebbia, G., et al. (2023) · mBio · doi:10.1128/mbio.01206-23 · Cited by 10

Determining the Reliability of Rapid SARS-CoV-2 Antigen Detection in Fully Vaccinated Individuals

Poopalasingam, N., Korenkov, M., Ashurov, A., Strobel, J., Fish, I., Hellmich, M., Gruell, H., Lehmann, C., Heger, E., & Klein, F. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105119 · Cited by 15

Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population

Carrat, F., Villarroel, P. M. S., Lapidus, N., Fourié, T., Blanché, H., Dorival, C., Nicol, J. T. J., Deleuze, J., Robineau, O., SAPRIS-SERO Study Group, et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11787-4 · Cited by 14

Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3–9-month intervals following two-dose inactivated vaccine (CoronaVac)

Liao, Y., Chen, Y.-P., Chen, B., Liang, Z., Hu, X., Xing, B., Yang, J., Zheng, Q., Hua, Q., Yan, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017590 · Cited by 13

Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China

Zhang, H., Hua, Q., Xu, N., Zhang, X., Chen, B., Xi-jun, M., Hu, J., Chen, Z., Yu, P., Lei, H., et al. (2023) · eLife · doi:10.7554/elife.84056 · Cited by 17

Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workersPreprint

Marking, U. W., Havervall, S., Greilert‐Norin, N., Bladh, O., Christ, W., Gordon, M., Ng, H., Blom, K. G., Phillipson, M., Mangsbo, S. M., et al. (2022) · medRxiv · doi:10.1101/2022.04.02.22273333 · Cited by 13

Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines

Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11

Ginseng Polysaccharide Enhances the Humoral and Cellular Immune Responses to SARS-CoV-2 RBD Protein Subunit Vaccines

Zhang, J., Feng, J., Huang, Y., Zhou, B., Li, B., & Zhang, R. (2023) · Vaccines · doi:10.3390/vaccines11121833 · Cited by 13

Severe breakthrough COVID-19 infections in Scotland—implications for immunisation programmes

Leshem, E., Nelson, K., & Lopman, B. A. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00413-6 · Cited by 12

A Single Dose of ChAdOx1 nCoV-19 Vaccine Elicits High Antibody Responses in Individuals with Prior SARS-CoV-2 Infection Comparable to That of Two-Dose-Vaccinated, SARS-CoV-2-Infection-Naïve Individuals: A Longitudinal Study in Ethiopian Health Workers

Gelanew, T., Mulu, A., Abebe, M., Bates, T. A., Wassie, L., Teferi, M., Fentahun, D., Alemu, A., Tamiru, F., Assefa, G., et al. (2022) · Vaccines · doi:10.3390/vaccines10060859 · Cited by 13

Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries

Bert, F., Scaioli, G., Vola, L., Accortanzo, D., Moro, G. L., & Siliquini, R. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127233 · Cited by 15

High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge

Ujjainiya, R., Tyagi, A., Sardana, V., Naushin, S., Bhatheja, N., Kumar, K., Barman, J., Prakash, S., Kutum, R., Bhaskar, A. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29404-3 · Cited by 10

In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant

Heinen, N., Marheinecke, C. S., Bessen, C., Blazquez‐Navarro, A., Roch, T., Stervbo, U., Anft, M., Plaza‐Sirvent, C., Buße, S., Klöhn, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1062210 · Cited by 10

SIRS epidemics with individual heterogeneity of immunity waning

Khalifi, M. E., & Britton, T. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111815 · Cited by 13

Rapid Cytokine Release Assays for Analysis of Severe Acute Respiratory Syndrome Coronavirus 2–Specific T Cells in Whole Blood

Törnell, A., Wiktorin, H. G., Ringlander, J., Arabpour, M., Nilsson, M., Nilsson, S., Kiffin, R., Lindh, M., Lagging, M., Hellstrand, K., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac005 · Cited by 11

Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine

Nantel, S., Bourdin, B., Adams, K., Carbonneau, J., Rabezanahary, H., Hamelin, M., McCormack, D., Savard, P., Longtin, Y., Cheng, M. P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.930252 · Cited by 12

Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan

Chao, C.-H., Cheng, D., Huang, S., Chuang, Y., Yeh, T., & Wang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1023943 · Cited by 11

Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity

Abdollahi, A., Afsharyzad, Y., Vaezi, A., & Meysamie, A. (2022) · Vaccines · doi:10.3390/vaccines10101708 · Cited by 12

Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models

González‐Domínguez, I., Abdeljawad, A., Lai, T. Y., Boza, M., McCroskery, S., Lemus, N., Slamanig, S., Singh, G., Warang, P., Yellin, T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524477 · Cited by 11

Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines

Kung, Y.-A., Huang, S., Huang, C., Liu, K., Huang, P.-N., Yu, K.-Y., Yang, S., Chen, C.-P., Cheng, C.-Y., Lee, I., et al. (2022) · Microbes and Infection · doi:10.1016/j.micinf.2022.105044 · Cited by 11

Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients

Ruggeri, E. M., Nelli, F., Giannarelli, D., Fabbri, A., Berrìos, J. R. G., Virtuoso, A., Marrucci, E., Mazzotta, M., Schirripa, M., Signorelli, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25558-8 · Cited by 10

An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals

Offersgaard, A., Hernandez, C. R. D., Feng, S., Marichal‐Gallardo, P., Holmbeck, K., Pihl, A. F., Fernandez-Antunez, C., Alzua, G. P., Hartmann, K. T., Pham, L. V., et al. (2023) · iScience · doi:10.1016/j.isci.2023.105949 · Cited by 10

Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID‐A Study

Ríos, S. S., Zamora, E. B. C., Céspedes, A. A., Rizos, L. R., Sánchez‐Jurado, P. M., Nievas, G. S., Romero, M. M., Sahuquillo, M. T. T., Señalada, J. J. B., Romero, A. M., et al. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17620 · Cited by 10

Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2

Markewitz, R. D. H., Juhl, D., Pauli, D., Görg, S., Junker, R., Rupp, J., Engel, S., Steinhagen, K., Herbst, V., Zapf, D., et al. (2022) · Vaccines · doi:10.3390/vaccines10050649 · Cited by 10

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective Cohort Study

Meyers, E., Deschepper, E., Duysburgh, E., Rop, L. D., Burghgraeve, T. D., Ngoc, P. V., Digregorio, M., Delogne, S., Coen, A., Clercq, N. D., et al. (2022) · Viruses · doi:10.3390/v14112361 · Cited by 12

COVID-19 Vaccination Effectiveness in the General Population of an Italian Province: Two Years of Follow-Up

Rosso, A., Flacco, M. E., Soldato, G., Martino, G. D., Martellucci, C. A., Carota, R., Benedictis, M. D., Marco, G. D., Luzio, R. D., Fiore, M., et al. (2023) · Vaccines · doi:10.3390/vaccines11081325 · Cited by 10

Variation in antibody titers determined by Abbott and Roche Elecsys SARS-CoV-2 assays in vaccinated healthcare workers

Nakai, M., Yokoyama, D., Sato, T., Sato, R., Kojima, C., & Shimosawa, T. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16547 · Cited by 10

Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers

Assaid, N., Arich, S., Charoute, H., Akarid, K., Ezzikouri, S., Maaroufi, A., & Sarih, M. (2022) · Vaccines · doi:10.3390/vaccines10030465 · Cited by 12

Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?

Stellini, R., Gianello, R., & Gomarasca, W. (2022) · Infection · doi:10.1007/s15010-022-01816-9 · Cited by 8

Decavanadate interactions with the elements of the SARS-CoV-2 spike protein highlight the potential role of electrostatics in disrupting the infectivity cycle

Favre, D., Harmon, J. F., Zhang, A., Miller, M. S., & Kaltashov, I. A. (2022) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2022.111899 · Cited by 10

Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination

Wang, F., Huang, B., Lv, H., Feng, L., Ren, W., Wang, X., Tang, L., Liu, Q., Wu, D., Zheng, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967051 · Cited by 10

Vertical Transmission and Maternal Passive Immunity post-SARS-CoV-2

Karimi, H., Mansouri, V., & Rezaei, N. (2023) · Future Virology · doi:10.2217/fvl-2023-0089 · Cited by 11

Strategies and safety considerations of booster vaccination in COVID-19

Meng, H., Mao, J., & Ye, Q. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2021.7082 · Cited by 12

Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine

Brill, L., Rechtman, A., Shifrin, A., Rozenberg, A., Afanasiev, S., Zveik, O., Haham, N., Levin, N., & Vaknin‐Dembinsky, A. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103863 · Cited by 9

SARS-CoV-2 Attack Rate and Population Immunity in Southern New England, March 2020 to May 2021

Tran, T. N.-A., Wikle, N. B., Yang, F., Inam, H., Leighow, S. M., Gentilesco, B. J., Chan, P. A., Albert, E., Strong, E. R., Pritchard, J. R., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.14171 · Cited by 7

Delayed and Attenuated Antibody Responses to Coronavirus Disease 2019 Vaccination With Poor Cross-Variant Neutralization in Solid-Organ Transplant Recipients—A Prospective Longitudinal Study

Liew, M. Y., Mathews, J., Li, A., Singh, R., Jaramillo, S. A., Weiss, Z., Bowman, K. A., Ankomah, P., Ghantous, F., Lewis, G. D., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad369 · Cited by 8

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patientsPreprint

Lin, S., Kennedy, N. A., Saifuddin, A., Sandoval, D. M., Reynolds, C. J., Seoane, R. C., Kottoor, S. H., Pieper, F. P., Lin, K., Butler, D. K., et al. (2021) · medRxiv · doi:10.1101/2021.11.10.21266168 · Cited by 9

Effectiveness of mRNA Booster Vaccine Against Coronavirus Disease 2019 Infection and Severe Outcomes Among Persons With and Without Immune Dysfunction: A Retrospective Cohort Study of National Electronic Medical Record Data in the United States

Sun, J., Zheng, Q., Anzalone, A. J., Abraham, A. G., Olex, A. L., Zhang, Y., Mathew, J., Safdar, N., Haendel, M. A., Segev, D. L., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae019 · Cited by 9

Long‐term effects of SARS‐CoV ‐2 vaccination in the nursing home setting

Rivasi, G., Bulgaresi, M., Bandinelli, C., Balzi, D., Tarantini, F., Tognelli, S., Lorini, C., Buscemi, P., Baggiani, L., Landini, G., et al. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17773 · Cited by 10

Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults

Dedroogh, S., Schmiedl, S., Thürmann, P., Graf, K., Appelbaum, S., Koß, R., Theis, C., Zia, Z., Tebbenjohanns, J., Thal, S. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-34961-8 · Cited by 11

Explicit modeling of antibody levels for infectious disease simulations in the context of SARS-CoV-2

Müller, S. A., Paltra, S., Rehmann, J., Nagel, K., & Conrad, T. (2023) · iScience · doi:10.1016/j.isci.2023.107554 · Cited by 9

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01721-6 · Cited by 248

SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general populationPreprint

Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2021) · medRxiv · doi:10.1101/2021.09.13.21263487 · Cited by 11

Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose

Yavlinsky, A., Beale, S., Nguyen, V. G., Shrotri, M., Byrne, T., Geismar, C., Fragaszy, E., Hoskins, S., Fong, W. L. E., Navaratnam, A. M. D., et al. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17914.1 · Cited by 10

Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study

Leong, D. P., Zhang, A., Breznik, J. A., Clare, R., Huynh, A., Mushtaha, M., Rangarajan, S., Stacey, H. D., Kim, P. Y., Loeb, M. B., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281673 · Cited by 10

Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose

Sanna, G., Marongiu, A., Firinu, D., Piras, C., Palmas, V., Galdiero, M., Atzori, L., Caria, P., Campagna, M., Perra, A., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01276-x · Cited by 1